1. Home
  2. HBAN vs NTRA Comparison

HBAN vs NTRA Comparison

Compare HBAN & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Huntington Bancshares Incorporated

HBAN

Huntington Bancshares Incorporated

HOLD

Current Price

$15.23

Market Cap

28.4B

Sector

Finance

ML Signal

HOLD

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$198.09

Market Cap

28.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HBAN
NTRA
Founded
1866
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.4B
28.0B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
HBAN
NTRA
Price
$15.23
$198.09
Analyst Decision
Buy
Strong Buy
Analyst Count
17
14
Target Price
$19.38
$259.07
AVG Volume (30 Days)
25.9M
1.1M
Earning Date
01-01-0001
05-19-2026
Dividend Yield
4.03%
N/A
EPS Growth
N/A
0.65
EPS
N/A
N/A
Revenue
N/A
$210,939,000.00
Revenue This Year
$50.66
$16.65
Revenue Next Year
$9.04
$19.22
P/E Ratio
$12.87
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.92
$125.38
52 Week High
$19.44
$256.36

Technical Indicators

Market Signals
Indicator
HBAN
NTRA
Relative Strength Index (RSI) 31.24 42.60
Support Level $15.17 $194.03
Resistance Level $16.28 $251.09
Average True Range (ATR) 0.45 8.14
MACD -0.11 0.21
Stochastic Oscillator 10.91 39.30

Price Performance

Historical Comparison
HBAN
NTRA

About HBAN Huntington Bancshares Incorporated

Huntington is a regional US bank with over $200 billion in assets and has a large presence, particularly in the Midwestern market. It offers a full suite of consumer deposit and lending services, along with commercial services focused on payments, investment management, capital markets, equipment financing, treasury management, and other common banking services.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: